Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 1;136(1):24–33. doi: 10.1097/CM9.0000000000002567

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0

This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Results from NMA of primary outcomes of schedules initiated with mRNA or non-replicating viral vector. (A) Evidence network of the neutralizing antibody against an original strain. (B) Evidence network of SAEs. The figure in each cell in the upper area refers to the OR of the schedule in the row against the schedule in the column, and the figure in each cell in the lower area refers to the OR of the schedule in the column against the schedule in the row. If no relevant information on SAEs or neutralizing antibody is reported in a comparison, the a dot will be used to fill the cell in the corresponding position. (C) GMR and 95% CI of comparisons (the results for SAEs are presented in the lower area, and the results for neutralizing antibodies are presented in the upper area). 1 ChAd + NVX 5: one dose of ChAdOx1 followed by NVX-CoV2373 5 μg; 1 mRNA-1273 + BNT 30: one dose of mRNA-1273 followed by BNT162b2 30 μg; 1 mRNA-1273 + mRNA-1273 100: one dose of mRNA-1273 followed by mRNA-1273 100 μg; 1 BNT + BNT 30: one dose of BNT162b2 followed by BNT162b1 30 μg; 1 BNT + ChAd 5: one dose of BNT162b2 followed by ChAdOx1 5 × 10¹⁰ viral particles; 1 BNT + mRNA-1273 100: one dose of BNT162b2 followed by mRNA-1273 100 μg; 1 BNT + NVX 5: one dose of BNT162b2 followed by NVX-CoV2373 5 μg; 1 ChAd + BNT 30: one dose of ChAdOx1 followed by BNT162b2 30 μg; 1 ChAd + ChAd 5: one dose of ChAdOx1 followed by ChAdOx1 5 × 10¹⁰ viral particles; 1 ChAd + mRNA-1273 100: one dose of ChAdOx1 followed by mRNA-1273 100 μg; 1 ChAd + no: one dose of ChAdOx1 only. CI: Confidence interval; GMR: Geometric mean ratio; NMA: Network meta-analysis; SAEs: Serious adverse events.